This HTML5 document contains 39 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n12http://linked.opendata.cz/resource/drugbank/drug/DB05492/identifier/drugbank/
n11http://linked.opendata.cz/resource/drugbank/drug/DB05492/identifier/chemspider/
n7http://bio2rdf.org/drugbank:
admshttp://www.w3.org/ns/adms#
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
owlhttp://www.w3.org/2002/07/owl#
n3http://linked.opendata.cz/ontology/drugbank/
n9http://linked.opendata.cz/resource/drugbank/drug/DB05492/identifier/pdb/
n4http://linked.opendata.cz/resource/drugbank/property/
xsdhhttp://www.w3.org/2001/XMLSchema#
n10http://linked.opendata.cz/resource/drugbank/drug/DB05492/identifier/pubchem-compound/

Statements

Subject Item
n2:DB05492
rdf:type
n3:Drug
n3:description
EpiCept NP-1 is a prescription topical analgesic cream designed to provide effective, long-term relief from the pain of peripheral neuropathies. Peripheral neuropathies are medical conditions caused by damage to the nerves in the peripheral nervous system. The peripheral nervous system includes nerves that run from the brain and spinal cord to the rest of the body. EpiCept NP-1 Cream is a patented formulation containing two FDA-approved drugs, amitriptyline (a widely-used antidepressant) and ketamine (an NMDA antagonist that is used as an anesthetic).
n3:generalReferences
# Sandroni P, Davis MD: Combination gel of 1% amitriptyline and 0.5% ketamine to treat refractory erythromelalgia pain: a new treatment option? Arch Dermatol. 2006 Mar;142(3):283-6. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/16549702 # Lynch ME, Clark AJ, Sawynok J, Sullivan MJ: Topical amitriptyline and ketamine in neuropathic pain syndromes: an open-label study. J Pain. 2005 Oct;6(10):644-9. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/16202956 # Lynch ME, Clark AJ, Sawynok J, Sullivan MJ: Topical 2% amitriptyline and 1% ketamine in neuropathic pain syndromes: a randomized, double-blind, placebo-controlled trial. Anesthesiology. 2005 Jul;103(1):140-6. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/15983466 # Oatway M, Reid A, Sawynok J: Peripheral antihyperalgesic and analgesic actions of ketamine and amitriptyline in a model of mild thermal injury in the rat. Anesth Analg. 2003 Jul;97(1):168-73, table of contents. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/12818961
n3:group
investigational
n3:indication
Investigated for use/treatment in neuropathy (diabetic) and pain (acute or chronic).
owl:sameAs
n7:DB05492
dcterms:title
Epicept NP-1
adms:identifier
n9:NP1 n10:5276854 n11:4440796 n12:DB05492
n3:mechanismOfAction
The mechanism(s) of action are unclear for Epicept. Both ketamine and amitriptyline inhibit N-methyl-D-aspartate receptors in neuronal preparations and may be involved in sensitization of tetrodotoxin-resistant Na+ currents in nociceptors by blocking Na+ channels. In producing antihyperalgesia with pretreatment, but not posttreatment, regimens, ketamine and amitriptyline resemble the profile of a ยต-opioid receptor agonist. In addition to the above effects, amitriptyline also inhibits noradrenaline, 5-HT, and adenosine uptake; inter-acts with opioid mechanisms; blocks Ca2+ channels; and blocks cholinergic, histamine H1, 5-HT2, and {alpha}-adrenergic receptors. Accordingly there are many possible mechanisms at work.
n3:toxicity
Mild sensitivity at application site
n3:IUPAC-Name
n4:271B4544-363D-11E5-9242-09173F13E4C5
n3:InChI
n4:271B454A-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n4:271B4549-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n4:271B4546-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n4:271B4547-363D-11E5-9242-09173F13E4C5
n3:SMILES
n4:271B4548-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n4:271B4542-363D-11E5-9242-09173F13E4C5
n3:logP
n4:271B4540-363D-11E5-9242-09173F13E4C5 n4:271B4543-363D-11E5-9242-09173F13E4C5
n3:logS
n4:271B4541-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Acceptor-Count
n4:271B4550-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n4:271B4551-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n4:271B454B-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n4:271B454C-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n4:271B454E-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n4:271B454D-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n4:271B454F-363D-11E5-9242-09173F13E4C5
n3:Bioavailability
n4:271B4556-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n4:271B4558-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n4:271B4559-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n4:271B4555-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n4:271B4554-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n4:271B4557-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n4:271B4545-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-
n4:271B4552-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n4:271B4553-363D-11E5-9242-09173F13E4C5